Guideline on the management of bleeding in patients on antithrombotic agents

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding

(2012) T. E. Warkentin et al.   BLOOD

Reversal of the anti-platelet effects of aspirin and clopidogrel

(2012) C. LI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model

(2011) Anne Godier et al.   ANESTHESIOLOGY

Protamine reversal of low molecular weight heparin

(2011) Joost J. van Veen et al.   BLOOD COAGULATION & FIBRINOLYSIS

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*

(2011) Margareta Blombäck et al.   BRITISH JOURNAL OF HAEMATOLOGY

Guidelines on oral anticoagulation with warfarin - fourth edition

(2011) David Keeling et al.   BRITISH JOURNAL OF HAEMATOLOGY

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

(2011) Elise S. Eerenberg et al.   CIRCULATION

Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor

(2011) Mariano A Giorgi et al.   EXPERT OPINION ON PHARMACOTHERAPY

RECOVERY OF PLATELET FUNCTION FOLLOWING DISCONTINUATION OF PRASUGREL OR CLOPIDOGREL MAINTENANCE DOSING IN ASPIRIN-TREATED SUBJECTS WITH STABLE CORONARY DISEASE: THE RECOVERY TRIAL

(2011) Matthew J. Price et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents

(2011) M. LEVI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Intravenous Thrombolytic Therapy for Acute Ischemic Stroke

(2011) Lawrence R. Wechsler   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peri-operative management of antiplatelet therapy in patients with coronary artery disease

(2011) Marco Cattaneo et al.   THROMBOSIS AND HAEMOSTASIS

Critical appraisal of ticagrelor in the management of acute coronary syndrome

(2011) James Nawarskas et al.   Therapeutics and Clinical Risk Management

Management of Thrombolysis-Associated Symptomatic Intracerebral Hemorrhage

(2010) Joshua N. Goldstein et al.   ARCHIVES OF NEUROLOGY

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Recombinant factor VIIa for unlicensed indications - a definite No or a cautious Maybe in selected patients?

(2010) Y. Sorour et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Safety of Recombinant Activated Factor VII in Randomized Clinical Trials

(2010) Marcel Levi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation

(2009) F. Ni Ainle et al.   BLOOD

Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents

(2009) M. A. CROWTHER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis

(2009) Jonathan R. Genzen et al.   TRANSFUSION

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents

(2008) M. A. Crowther et al.   BLOOD

Parenteral Anticoagulants

(2008) Jack Hirsh et al.   CHEST

Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats

(2008) B. LAURITZEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Reversal of the inhibitory effect of Fondaparinux on Thrombin generation by rFVIIa, aCCP and PCC

(2008) H. Desmurs-Clavel et al.   THROMBOSIS RESEARCH